European Patent Office Upholds Synergy Pharmaceuticals' Grant of Claims to Plecanatide

Synergy Pharmaceuticals, Inc. a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the successful outcome of the Oral Hearing held December 14, 2011 before the Opposition Division of the European Patent Office regarding Synergy's granted patent on plecanatide. Synergy's European Patent EP 1 379 224 was originally opposed in May 2010 by Ironwood Pharmaceuticals IRWD +2.50% and another party. At the Oral Hearing, attended by Synergy and Ironwood representatives, the Opposition Division maintained Synergy's patent, in amended form. Specifically, The Opposition Division upheld the validity of the claims in Synergy's EP patent that relate to Synergy's lead drug candidate plecanatide. Written reasons consistent with the oral ruling are expected within a few months."We are pleased that the proceedings at the European Patent Office upheld the novelty and inventiveness of plecanatide," said Gary S. Jacob, Chief Executive Officer of Synergy.